A complex of Boswellia serrata resin extract standardized to 30% AKBA and Bengal quince fruit extracts, branded as AlvioLife by PLT Health Solutions, was evidenced to support respiratory function in healthy participants in a randomized, placebo-controlled human clinical study awaiting publication.
 
For six weeks, healthy participants with self-reported air pollution sensitivity took either 200 mg/day of AlvioLife  or a matching placebo. Subjects taking AlvioLife experienced statistically significant improvements from baseline and compared to placebo for lung function, lung capacity and aerobic exercise capacity. In addition to these results, the study showed reductions in reported upper respiratory tract symptoms (Wisconsin Upper Respiratory Symptom Scale) and improved psychological well-being. Positive changes in immune (CD4+) and inflammatory (IL-8) biomarkers were also shown. This is the second clinical study of AlvioLife to demonstrate support for healthy respiratory activity and perceived well-being.
 
AlvioLife supplementation was associated with improved lung function (FEV1) by up to 16%, lung capacity (FVC) by up to 30%, and aerobic exercise capacity by up to 7% (six-minute walk test). It reduced upper respiratory tract symptoms according to WURSS-21 by up to 40%, improved perceived immune status (ISQ) in as early as three weeks, improved psychological well-being scores by up to 18% in self-reporting, and improved the percentage of CD4+T helper cells.
 
In an earlier double-blind study involving subjects with bronchial asthma, 36 subjects took AlvioLife at 200 mg per day or a matching placebo for 56 days. AlvioLife conferred significant improvements in the clinical parameters, the emotional function (p+0.0305), and asthma symptoms scores (p=0.0002) were improved even at 14 days compared to placebo.
 
“It’s easy to forget how many aspects of our lives are dependent on respiratory health – from overall health to emotional well-being to physical performance. And factors like environmental pollution can challenge optimal respiratory health,” said Seth Flowerman, president and CEO of PLT Health Solutions. “AlvioLife can function as a standalone ingredient to support respiratory function for people who have respiratory sensitivities or live in higher pollution areas, as well as a component in immune health formulations – since the issue of respiratory health is so vital to the immune health equation. For companies looking to differentiate and enhance their immune health formulations, AlvioLife offers some unique benefits,” he added.
 
According to PLT, AlvioLife contains a Boswellia serrata resin extract standardized to 30% 3-O-acetyl-11-keto-beta-boswellic acid (AKBA) along with Bengal quince fruit extracts. This combination of natural extracts is reported to work via mechanisms that help balance the inflammatory response, such as 5-LOX inhibition activity, which is involved in airway inflammation.
 
“This new study, conducted on healthy subjects, brings the unique potential of AlvioLife into focus. The new clinical study points to the importance of respiratory health in all phases of our lives. Once again, we demonstrated improved lung function, but we can now see how this also translates into improvements in lung capacity, aerobic exercise capacity and a reduction in upper respiratory tract symptoms. The measurements of the well-being index suggest that people are indeed happier when they breathe easier,” said Jennifer Murphy, director of innovation and clinical development for PLT. “For all these reasons, we are seeing interest in AlvioLife as a complementary ingredient in the fast-growing immune health category.”